Welcome to our dedicated page for Walgreen Boots news (Ticker: WBA), a resource for investors and traders seeking the latest updates and insights on Walgreen Boots stock.
Walgreens Boots Alliance, Inc. became a privately owned company after Sycamore Partners completed its acquisition of WBA in August 2025. News about the former public issuer centers on the transition of Walgreens and related businesses under private ownership, including Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD.
Recurring company updates also cover Walgreens' U.S. retail pharmacy and health-services operations, specialty pharmacy limited-distribution drug relationships, and capital actions tied to WBA and Walgreen Co. senior notes, including tender offers and consent solicitations.
Walgreens Boots Alliance (Nasdaq: WBA) appointed Roz Brewer as CEO effective March 15, 2021, succeeding Stefano Pessina, who transitions to Executive Chairman. Brewer, previously COO at Starbucks, brings expertise in digital transformation and operational leadership. Her appointment follows a detailed search to leverage WBA's growth opportunities in healthcare. The board anticipates Brewer's focus on customer experience and operational rigor will drive sustainable growth. Skinner, the outgoing chairman, emphasized WBA's strong position in community healthcare, expressing confidence in the future under Brewer's leadership.
Walgreens has successfully administered over 1 million COVID-19 vaccinations across vulnerable populations, including long-term care facilities. As part of the CDC Pharmacy Partnership, vaccinations began on Dec. 21 and are set to complete first doses in skilled nursing facilities by Jan. 25. Walgreens aims to provide access to those prioritized by state and jurisdiction guidelines, with current eligibility focusing on healthcare workers and individuals aged 65 and older. The company continues to follow strict federal and state protocols for vaccination reporting.
Walgreens Boots Alliance (Nasdaq: WBA) will host its virtual annual stockholders' meeting on Jan. 28, 2021, at 8:00 a.m. CST, accessible via their investor relations website. A live audio webcast will be available, with a replay archived for 12 months. Executive Chairman Jim Skinner and CEO Stefano Pessina will present, followed by a Q&A session for attendees. WBA, a global leader in pharmacy and healthcare, operates over 21,000 stores in more than 25 countries, focusing on community health and sustainability.
No7 announces the launch of its latest product, Laboratories Resurfacing Peel 15% Glycolic Acid, aimed at providing an at-home alternative to professional dermatological treatments. The peel utilizes glycolic acid, known for its exfoliating properties, along with gluconolactone for improved efficacy and skin tolerance. Dermatologist Dr. Tess Mauricio endorses the product, noting visible improvements in skin texture and tone after usage. The peel retails for $39.99 and is available online.
Walgreens has issued a statement in response to President-elect Biden’s COVID-19 Update, expressing support for his plan to boost vaccine distribution through pharmacies. Walgreens cites its extensive network and experience, stating it is well-positioned to administer COVID-19 vaccines across the nation. The company has been vaccinating vulnerable populations in long-term care facilities since December and is ready to broaden its vaccine efforts in local communities. Walgreens aims to provide convenient and equitable access to vaccines for all Americans.
OFP Real Estate, LLC has acquired a net-leased investment property tenanted by Walgreens Boots Alliance (WBA) in the Cleveland, Ohio metro area. This acquisition, which marks OFP's first for 2021, was secured with a long-term lease, ensuring stable and predictable returns. The purchase increases OFP's net-lease investments to over $45,000,000 across five states, with aims to exceed a $150,000,000 acquisition target by year-end. The firm focuses on income-producing investments from leading retail tenants.
Walgreens is enhancing its financial services by partnering with Synchrony and Mastercard to launch credit and prepaid debit cards. These offerings will integrate with the myWalgreens loyalty program, providing customers with cash rewards and additional benefits at over 9,000 Walgreens locations and beyond. The cards aim to boost customer engagement and create new revenue streams, with features like contactless payments and health-focused rewards. The new financial products are expected to be available in the second half of this year, reflecting Walgreens' commitment to improving health and wellness payment solutions.
Walgreens Boots Alliance (Nasdaq: WBA) has announced a majority investment in iA, a provider of software-enabled automation solutions for the pharmacy sector. This strategic investment aims to enhance iA's pharmacy automation offerings, thus streamlining medication dispensing and enabling pharmacists to focus more on patient care. The move aligns with the growing demand for efficient healthcare solutions, especially post-COVID-19, aiming to modernize pharmacy operations and improve patient outcomes.
Walgreens Boots Alliance (WBA) reported first-quarter fiscal 2021 results, with sales of $36.3 billion, a 5.7% increase from the prior year. Despite strong sales, the company faced an operating loss of $440 million, largely due to a $1.5 billion equity charge from AmerisourceBergen. Net loss was $308 million, with adjusted EPS down 11.2% to $1.22. The company maintains its fiscal 2021 guidance for low single-digit growth in adjusted earnings per share. Walgreens continues its critical role in COVID-19 vaccinations, with over 2.8 million tests administered.
Walgreens Boots Alliance (Nasdaq: WBA) has significantly increased its investment in VillageMD to establish 600 to 700 Village Medical at Walgreens clinics across more than 30 U.S. markets over the next four years. This initiative builds on previous plans, with WBA completing a $750 million investment as part of a larger $1 billion commitment. The clinics aim to provide accessible, coordinated healthcare, particularly in underserved areas, emphasizing the integration of pharmacists into primary care teams for enhanced patient support.